Seattle Genetics (SGEN) Delivers at ASH - Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/20/2026
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Loop Capital downgrades Apple, sees no recovery of cut iPhone shipments
- Wells Fargo says S&P 500 buy signal emerges as investors turn excessively bearish
- ByteDance, Alibaba and Tencent order $35 billion of Nvidia chips: Reuters
Seattle Genetics (SGEN) Presents Ongoing SGN-LIV1A Phase 1 Data at SABCS
December 10, 2015 8:07 AM ESTSeattle Genetics, Inc. (Nasdaq: SGEN) today presented data from an ongoing phase 1 clinical trial evaluating SGN-LIV1A, an antibody-drug conjugate (ADC) in development for patients with LIV-1-expressing metastatic breast cancer (MBC), at the 38th San Antonio Breast Cancer Symposium (SABCS) taking place in San Antonio, Texas, December 8-12, 2015. SGN-LIV1A consists of a humanized... More
Seattle Genetics (SGEN) ADCETRIS Frontline Non-Hodgkin Lymphoma Data Presented at ASH
December 7, 2015 4:32 PM ESTSeattle Genetics, Inc. (Nasdaq: SGEN) today highlighted data presentations evaluating ADCETRIS (brentuximab vedotin) in frontline non-Hodgkin lymphoma at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, Florida, December 5-8, 2015. The data include an oral presentation highlighting updated results from an ongoing phase 2 clinical trial evaluating ADCETRIS in combination with chemotherapy for newly diagnosed, high risk diffuse large B-cell lymphoma (DLBCL) patients. In addition, a poster presentation highlights a three-year durability analysis from a phase 1 clinical trial of ADCETRIS in combination with chemotherapy for the treatment of newly... More
Seattle Genetics (SGEN) Announces Presentation of SGN-CD19A Data in NHL a ASH
December 7, 2015 6:28 AM ESTSeattle Genetics, Inc. (Nasdaq: SGEN) highlighted clinical data with denintuzumab mafodotin (SGN-CD19A; 19A) in B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL) and B-lineage acute lymphocytic leukemia (B-ALL), presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, Florida, December 5-8, 2015. Preclinical data from a novel antibody-drug conjugate (ADC) program called SGN-CD19B in B-cell malignancies will also be featured in an oral presentation. About 85 percent of non-Hodgkin lymphomas (NHL) are B-cell lineage, and CD19 is broadly expressed across all subtypes of B-cell... More



